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Down’s syndrome (DS, trisomy 21) represents a complex genetic abnormality that leads to pathology in later life that is similar
to Alzheimer’s disease (AD). We compared two cases of DS with APOE ε3/3 genotypes, a similar age at death, and comparable
amyloid-beta42peptide(Aβ42)burdensinthebrainbutthatdiﬀeredmarkedlyintheseverityofAD-likepathology.Oneexhibited
extensiveneuroﬁbrillarypathologywhereastheothershowedminimalfeaturesofthistype.ComparableloadsofAβ42couldrelate
tothecases’similarlife-timeaccumulationofAβduetotrisomy21-enhancedmetabolismofamyloidprecursorprotein(APP).The
cases’ signiﬁcant diﬀerence in AD-like pathology, however, suggests that parenchymal deposition of Aβ42, even when extensive,
may not inevitably trigger AD-like tau pathology (though it may be necessary). Thus, these observations of a natural experiment
may contribute to understanding the nuances of the amyloid cascade hypothesis of AD pathogenesis.
1.Introduction
Down’s syndrome (DS), caused by an additional chro-
mosome 21, most commonly underlies genetic mental
retardation. Alzheimer’s disease (AD) is the most common
neurodegenerative disease causing dementia. DS is a strong
risk factor for dementia that is very similar to AD. DS’
prevalence of dementia increases with age: 8% before age
of 50, 55% before age of 60, and 75% after age of 60 years.
Sporadic AD manifests increasingly after age of 60 years to
aﬀect1in4atageof85years[1].AD-likepathologydevelops
inevitably in DS brains after age of 40 and stages similar to
sporadic AD are recapitulated and accelerated in DS brains
[2]. The earliest changes in young DS brains (<30 years)
consistofintracellularaccumulationofamyloid-betapeptide
(Aβ) in neurons and astrocytes, followed by deposition
of extracellular Aβ with formation of diﬀuse plaques and,
ﬁnally,theappearanceofneuriticplaquesandneuroﬁbrillary
tangles [3].
The Aβ peptide is a product of two sequential cleavages
of the receptor-like amyloid precursor protein (APP). The
proteases involved are β-secretase (identiﬁed as the aspartyl
protease BACE-1, the beta-site APP-cleaving enzyme) and
γ-secretase, a multimeric complex containing presenilin.
Alpha-secretase cleaves within the Aβ polypeptide releasing
nonamyloidogenic fragments. Gamma-secretase can release
either Aβ40 or Aβ42, which has been reported to aggregate
more and be cytotoxic. Secreted Aβ can become degraded
by metalloproteases or be metabolized through uptake
mediated by apolipoprotein E (ApoE) [4–6].
The reason why DS patients in later midlife frequently
develop dementia and inevitably exhibit AD-like pathology2 International Journal of Alzheimer’s Disease
appears to be related to the extra copies of the APP
and BACE-2 genes, both located on chromosome 21 in
the obligate DS region at 21q22.3, resulting in abnormal
processing of APP [7, 8]. BACE-2, an aspartic protease
homologous to BACE-1, also cleaves at beta-sites but with
al o w e ra ﬃnity compared with BACE-1. While BACE-2
does not play a major role in sporadic AD pathogenesis,
its increased expression in DS patients likely plays a more
prominent role in causing increased Aβ levels and plaque
deposition in this population [7]. BACE-2 is overexpressed
in fetal DS brains. It cleaves APP at its beta-site and at a
site within Aβ (yielding nonamyloidogenic fragments) [7].
On the other hand, Cheon et al. [8] found overexpression of
APP in adult DS brains but described similar BACE-1 and
BACE-2 expression to that of controls whereas in early fetal
DSbrainstheyfoundnosigniﬁcantdiﬀerencesinexpression.
Consequently, life-long deposition of Aβ takes place in DS
brains including Aβ42, a critical component of amyloid
plaque formation that is widely accepted as initiating the
amyloid cascade of AD pathology [5, 6]. This view, however,
is being challenged [9].
According to the amyloid cascade hypothesis of Hardy
and Higgins [10], accumulation and aggregation of Aβ is the
primary cause of AD, including an inﬂammatory response
followed by neuritic injury, hyperphosphorylation of tau
protein, and formation of neuroﬁbrillary tangles (NFTs),
leading ultimately to neuronal dysfunction and cell death.
This hypothesis of AD pathogenesis may be particularly
applicable to DS/AD because of the inevitable development
of AD pathology in older DS brains [2] and of DS’
abnormalities in APP (and BACE-2) metabolism with life-
long overproduction of Aβ [7, 8]. Even so, the present study
challenges a central role played by Aβ42 in AD pathogenesis
because two similar cases of DS with respect to age at death
andtheAPOEgenotypediﬀeredmarkedlyinNFTsandsenile
plaques in spite of having comparable Aβ42 loads.
2.MaterialandMethods
The patients’ brain and spinal cord were obtained at
restricted autopsy (patient 1) and unrestricted autopsy
(patient 2) using standard methods. After a 2-week ﬁxa-
tion in 10% buﬀered formalin, the brain and spinal cord
were examined grossly and microscopically. Representative
histological sections were obtained from each cerebral lobe,
hippocampus, central gray nuclei, brain stem, cerebellar
cortex, dentate nucleus, and available spinal cord. Additional
sections were obtained from abnormalities including an
infarct in case 1. Routine neurohistological sections were
prepared at the University of Cincinnati Hospital and
additional immunohistochemical studies and determination
of the APOE genotypes were carried out at the University of
Indiana’s Alzheimer’s Disease Center.
Tissue was processed according to standard protocols for
embedding the brain in paraﬃn and each block was stained
with hematoxylin and eosin (H&E). Immunohistochemistry
was performed with positive and negative controls using
antibodies speciﬁc for the following:
(i) phosphorylated tau including Tau-5 (Neomarkers,
Fremont, CA 94555, pretreated with CC1-mild using
Ventana method iVIEW DAB Kit, 1:2000, incubated
for 16 minutes at 42◦C) and AT8 (Innogenetics,
Antwerp, Belgium),
(ii) amyloid-β (Aβ) (Elan Pharmaceuticals, 1:100)
including 10D5 (target antigenic region on the Aβ
molecule is peptide 3–6) and 21F12 (target antigenic
region on the Aβ-molecule is peptide #42),
(iii) glial ﬁbrillary acidic protein (GFAP, DakoCytoma-
tion, Carpinteria, 1:100),
(iv) α-synuclein (α-synuclein, Neomarkers, Fremont, CA
94555, prediluted using the Ventana method iVIEW
DAB Kit, incubated 32 minutes at 37◦C) .
Special stains (with positive controls) included Congo red
(Ventana, Tucson, Arizona, using the Ventana method,
Congo Red Kit, Nexes Special Stainer) which was viewed
under rhodamine ﬂuorescent light to enhance detection of
small amounts of ﬁbrillary amyloid, Luxol fast blue/H&E
and Woelcke for myelin, Bodian silver impregnation staining
axons, and AD pathology and thioﬂavin S which highlights
AD pathology viewed under ﬂuorescent light.
2.1. Semiquantitative Assessment of NFT and of Aβ. Loci
having either tau or Aβ42 immunoreactivity in either of the
two cases were examined. The density of NFTs was assessed
semiquantitatively using two IHC stains for tau pathology
(AT8 and tau5). Each estimate was carried out within the
region of interest showing the apparently highest density of
NFT. This region was viewed at a magniﬁcation of 400X
and within this ﬁeld all nerve cells and those with NFT
were counted yielding an NFT density expressed as a % of
neurons. The results derived with the two IHC methods were
then compared by plotting them as a scatter plot with a
linear regression line. The 18 data pairs available yielded a
signiﬁcant correlation (r2 = 0.6419, P < .001) validating the
use of either method’s highest NFT density to be entered in
Table 1.
The density of Aβ42 plaques with 21F12 antibodies and
of ﬁbrillar amyloid plaques with the Congo-red method
wassimilarlyassessed.Again,withineachβ-amyloid-positive
locus the area with the apparently highest plaque density
was selected. The number of plaques was estimated at
a magniﬁcation of 100X using a modiﬁed CERAD scale
listed in Table 1. The presence of vascular amyloid was also
recorded.
DNA was extracted from cerebellar tissue to determine
theAPOEgenotypeusingmethodsdescribedelsewhere[11].
3. Results
3.1. Clinical History. Case 1 was a 48-year-old Caucasian
man with typical features of Down’s syndrome, severe
mentalretardation,superimposeddementia,andspasticgait.
For several years prior to his demise, he had developed
progressive dementia. He also suﬀered from generalized
tonic-clonic seizures late in the course of his dementia.International Journal of Alzheimer’s Disease 3
Table 1: Semiquantitative assessment of AD changes.
Location
Tau-positive NFTs, % Aβ42 (21F12) Congo-red
Case 1 Case 2 Case 1 Case 2 Case 1 Case 2
Hippocampus/entorhi 47 59 C+ C+ C, Vx A
Middle temporal gyrus 80 0 threads C+ C+ — 0
Superior temporal g 40 0 threads C+ C+ C 0
Middle frontal gyrus 51 1 C+ C+ C− 0
Frontal (ipsila infarct) 41 — C+ — C, Vx —
Frontal (control infarct) 18 — C+ — C−,V x —
WM stray neurons 70 0 B A — 0
Insular cortex 70 — C+ — C —
Parietal lobe 42 0 C+ C+ C,Vx 0
Calcarine cortex 18 0 C+ C+ — 0
Caudate nucleus 10 0 C+ C+ B —
Putamen 5 0 C+ C+ B+ —
Globus Pallidus 22 0 B C 0 —
Dorsomedial thalamus 62 1 C A — 0
Centromedial thalamus 23 0 C 0 — 0
Pulvinar 15 — — — B —
Lateral geniculate body 0 — C− ———
Medial geniculate body 0 — — — — —
Hypothalamic nuclei 46 0 C C B+ 0
Amygdala 73 2 C+ C+ — —
Nucleus basalis Meynert 35 — — — — —
Substantia nigra 46 1 C− 0B0
Dorsal raphe n. 45 5 A B+ B 0
Nucleus rubber 0 0 — A 0 0
Mesenceph. reticular f. 22 — B — 0 0
Pontine nuclei 0 0 A 0 0 0
Pontine raphe n. 23 0 0 0 — 0
Locus coeruleus 16 8 0 0 0 0
Pontine tegmentum 24 — B+ — B 0
10th cranial nerve 8 0 C− 0—0
Medullary reticular f. 20 0 B+ 0 — 0
Cerebellar cortex 0 0 C∗,V x C ∗,V x 0 ,V x 0
NFTs = Neuroﬁbrillary tangles; expressed as percent of nerve cells aﬀected by NFTs per 400X ﬁeld.
Threads = neuropil threads present without NFT.
Amyloid plaque frequency per 100X ﬁeld: A = 1–4; B = 5–9; B+ = 10–19; C−= 20–29; C = 30–50; C+ => 50.
Vx = amyloid-positive vessels.
— = no data; 0 = absent; ∗large, diﬀuse plaques in the molecular layer covering ∼40% of the area.
Red/yellow shading indicates data pairs with divergent/similar results of cases 1 and 2, respectively.
During the last years of his life, he needed total care. He had
swallowing diﬃculties with a high risk for aspiration, bowel,
and bladder incontinence and was wheelchair bound due
to bilateral spasticity. On exam, he had no ability to follow
commands, but withdrew all extremities to painful stimuli,
showed upper gaze palsy, and increased plantar ﬂexion tone.
He had full range of movement in both upper and lower
limbs and absence of involuntary movements. He had a
spasticposturewithahighriskforfalls.Forthelast3months
of life, he received hospice care. An autopsy was restricted to
the brain and upper spinal cord.
Case 2 was a 46-year-old Caucasian man with typical
featuresofDown’ssyndromeandmildmentalretardation.In
contrast to case 1, he had not developed dementia as his level
of cognitive functioning was stable for at least the last decade
and he was able to take careof himself. On exam, he followed
commands, he was cooperative, and his neurological exam-
ination was within normal limits. During the last year, he
had chronic back pain due to intervertebral disc herniation
and stenotic ﬁbrosis with compression of the spinal cord
for which he underwent a laminectomy and fusion of T7
through L1 vertebrae two weeks prior to death. Following4 International Journal of Alzheimer’s Disease
surgery, he recovered without complications, regained his
base level of cognitive function, and was transferred to a
rehabilitation center. There he developed an acute right
common femoral deep venous thrombosis, conﬁrmed by
ultrasound exam, for which he was treated. He died two days
later. A full autopsy was performed.
3.2. Autopsy Findings. Case 1: At autopsy, performed 25
hours postmortem, the body appeared to be one to two
decades older than his age of 48 years. He showed typical
stigmata of Down’s syndrome. The fresh brain weighed
1020gm (average for gender and age = 1430gm). The
cerebral convexities revealed diﬀuse cortical atrophy and
ac y s t i ci n f a r c t ,3× 3 × 2cm, aﬀecting the left inferior
frontal gyrus anterior to the precentral gyrus. The superior
temporal gyri were narrower than normal bilaterally, as
is often seen in Down’s syndrome. The lateral ventricles
were moderately enlarged, with symmetrical dilatation of
the frontal, temporal, and occipital horns (hydrocephalus
ex vacuo). The upper cervical spinal cord revealed no gross
pathology.
Microscopy conﬁrmed a fully organized cortical-
subcortical infarct extending into the internal capsule and
putamen. The ipsilateral corticospinal tract was mildly
atrophied at all levels, including the available upper
spinal cord showing myelin pallor of the right (crossed)
corticospinal tract. The spinal cord lacked other pathologic
changes. Additionally, microscopic intracortical infarcts
were found in the frontal lobes. The hippocampus revealed
bilateral sclerosis with loss of pyramidal neurons in the
CA1/Sommer sector and gliosis. The cerebellar cortex
showed foci with Purkinje and granular cell loss and
Bergmann gliosis. These ischemic lesions were all located
in brain regions with prominent vascular amyloidosis but
without other micro- or macrovascular pathology. Cerebral
amyloid angiopathy-associated infarcts occur in DS with AD
pathology [12].
PathologicchangestypicalofADwerewidespreadwithin
the cerebral cortex and also involved subcortical structures.
They included granulovacuolar degeneration (hippocam-
pus), neuroﬁbrillary tangles (NFTs), neuropil threads, amy-
loid and neuritic senile plaques (SPs), and neuronal loss
with gliosis. The distribution and semiquantitative density
of NFT, Aβ42, and Congo-red-positive amyloid plaques is
shown in Table 1. According to CERAD criteria, the high
density of senile plaques in widespread neocortical regions
indicates a score C and a deﬁnite AD diagnosis [13]. NFT in
thevisualcortexassignsaBraakstageof6/6whileAβ plaques
in the cerebellar cortex indicate the most advanced stage 5 of
Aβ pathology [14,15].
The APOE genotype in this patient was APOE ε3/3.
Case 2: At autopsy, performed 14 hours postmortem, the
body appeared to be the oﬀered age of 46 years. Stigmata
of Down’s syndrome included, in addition to characteristic
facial features, a short neck with webbing, bilateral fusion
of the 2nd and 3rd and 4th and 5th toes, and a small brain
with a low fresh brain weight of 1080gm (average for gender
and age = 1430gm) with bilateral smallness of the superior
temporalgyri.Thebrainandspinalcordfailedtorevealother
gross abnormalities and the ventricular system was normal.
Autopsy established as cause of death a saddle pulmonary
thromboembolus and bilateral multiple pulmonary emboli
with focal hemorrhagic infarctions while the site of a T7-L1
laminectomy was without complications.
Microscopic CNS examination showed pathologic
changes of AD to be limited to the hippocampus,
entorhinal, and transentorhinal cortex while deposits
of Aβ42 were extensive and widespread. The distribution
and semiquantitative density of NFT, Aβ42, and Congo-red-
positive amyloid plaques are shown in Table 1 where they
can be compared to case 1. Absence of neocortical senile
plaques assigns a score of 0 according to CERAD criteria
(absence of AD), while the limited distribution of NFT
assigns a Braak stage of 2/6 [13, 14].
The APOE genotype in this patient was also APOE ε3/3.
4. Comparison of the Two DS Cases
Table 1 aﬀords a detailed comparison of the two cases’
distribution and extent of NFT, Aβ42 depositions, and
Congo-red-positive, ﬁbrillar amyloid plaques.
A main ﬁnding is the two cases’ comparable Aβ42-load
(as detected by 21F12-immunohistochemistry). The two
cases’ Aβ42 deposits are extensive and closely similar in the
cerebral and cerebellar cortex while subcortical loci are more
variable; overall, they are found in 93% of sites in case 1 and
in 70% of sites in case 2 and the highest C+ score (deﬁned in
Table 1)a ﬀects 43% and 39% of sites, respectively, in cases 1
and 2.
Comparison of Aβ42 in cases 1 and 2 with Wilcoxon’s
range test for paired observations shows no signiﬁcant
diﬀerence between the two cases (P > .10). Yet, in contrast to
their similar Aβ42load,thetwocasesdiﬀer signiﬁcantly with
respect to NFT and ﬁbrillar (Congo-red-positive) amyloid
plaques (Wilcoxon’s range test for paired observations,
P < .01,resp.).TheseobservationsarehighlightedinTable 1:
yellow shading indicates cases 1/2-data pairs with similar
pathology while red shading characterizes those that diﬀer
in their extent of pathological changes. The yellow or similar
data pairs are prevalent in the Aβ42 column while they are
uncommon or absent in the NFT and Congo-red columns.
Also, Figure 1 illustrates the two cases’ similar Aβ42 plaque
density and their marked diﬀerence of NFT in the middle
prefrontal gyrus.
Analysis of the association of Aβ with NFT shows that
all of the 15 Congo-red-positive sites also have NFTs while
among the 42 sites with Aβ42 plaques only 28 (2/3) also have
NFTs. The number of sites and the density of Aβ42 plaques
tend to be higher than those of Congo-red-positive plaques.
The locus coeruleus and pontine raphe nucleus stand out for
having NFT without Aβ and the cerebellar cortex for diﬀuse
Aβ42 plaques without NFT.
Alpha-synuclein IHC was negative throughout except for
the amygdala where mild focal cytoplasmic positivity was
seen on two sections. Of note is that the pigmented nuclei
in the brain stem (10th cranial nerve motor nucleus, locusInternational Journal of Alzheimer’s Disease 5
(a) (b)
(c) (d)
Figure 1: Photomicrographs illustrating the two cases’ similarity of amyloid Aβ42 plaques and marked diﬀerence in AD-like pathology.
Panel (a) shows tau pathology with NFT and neuropil threads of case 1 which are absent in case 2 (panel (b)). Panels (c) and (d) show
equally high Aβ42 plaque densities of cases 1 (c) and 2 (d). Location: prefrontal cortex (middle frontal gyrus); immunohistochemistry: tau-5
((a) and (b)) and 21F12 ((c) and (d)); magniﬁcation: 400X ((a) and (b)) and 100X ((c) and (d)).
coeruleus, and substantia nigra) are α-synuclein negative
(nuclei that tend to be aﬀected before or together with the
amygdala in Lewy body disease [15]).
5. Discussion
As in the original description of the eponymous disease by
Alois Alzheimer, case studies can contribute to mechanistic
hypotheses of disease pathology. The present description of
two DS cases can be thought of as a natural experiment that
could contribute to understanding the complex pathogenesis
of AD due to their genetic abnormality with similarly
extensive amyloid deposition in the brain but diﬀering in
AD-like pathology. The two cases had a similar life span (46
and 48 years), the same APOE genotype (APOE ε3/3), and
similar distribution and density of Aβ42 plaques but diﬀered
markedly in the extent of NFT and Congo-red-positive
amyloid plaques: one exhibiting advanced pathology and
dementia (case 1) with the other showing only limited, early
changes and no apparent cognitive deterioration (case 2).
By CERAD criteria, based on Congo-red-positive and tau-
positive neuritic (or dense-core) plaques, case 1 received a
score C (consistent with deﬁnite AD) and case 2 a score 0
(absence of AD) [13]. Using the NFT-based Braak stages,
case 1 was at the ultimate stage 6 and case 2 at an early stage
2[ 14]. In other words, one case ﬁt the pathological criteria
for a diagnosis of AD whereas the other did not.
In DS, AD-like pathology develops in relation to a
direct gene dosage eﬀect of trisomy 21 which results in
overexpression of APP (and BACE-2) and probably life-long
deposition of Aβ [7, 8, 16]. DS is also characterized by
premature aging and AD-like pathology at about half the
age of sporadic AD. The pattern of NFT and senile plaque
formation has been found to be similar in sporadic AD and
DS suggesting that they may share the same mechanisms
[17].
The similarity in Aβ42 loads in these two cases suggests
that the DS-based alteration of APP metabolism with over-
production and deposition of Aβ was similar. This ﬁnding
argues against the possibility that the two cases diﬀered with
respectoffullversusmosaictrisomy(withoutbeingformerly
ruled out).
Together withthesimilar Aβ42loadsof thetwocases,the
marked diﬀerence in NFT and Congo-red-positive plaque
pathology and diﬀerence in dementia may have bearing on
the amyloid cascade hypothesis that states that accumulation
and aggregation of Aβ is the primary cause of AD pathology
[10].ThecomparableAβ42loadfoundatthesameageinour
two cases would have been expected to have triggered similar6 International Journal of Alzheimer’s Disease
downstream events of NFT, senile plaques, and neuronal
loss with gliosis but resulted in extreme diﬀerences (at the
time of autopsy). Of course, it is possible, even likely, that
similar pathology would have developed with additional
time in the second case, but the diﬀerence in neuroﬁbrillary
pathology in the presence of similar amyloid deposition is
striking.
About a decade and a half after the amyloid hypothesis
was ﬁrst proposed, cleavage of amyloid precursor protein to
release amyloid-beta peptide has remained a well-accepted
hypothesis of AD pathogenesis and has generated multiple
therapeutic approaches [18]. However, this hypothesis is not
without critique [9, 19] and extensive eﬀorts in targeting the
removal of amyloid plaques from the brain of patients with
ADhavesofarbeendisappointing.Neitherplaque-removing
vaccines nor the gamma-secretase modulator tarenﬂurbil
have demonstrated clinical beneﬁts [20]. Furthermore,
dimebolin (an antihistamine) has been reported to result in
clinical improvement in AD while increasing amyloid load
[21, 22].
Although the present observations question a direct
dose-dependent eﬀect of Aβ42 in causing AD pathology,
they do not negate the strong evidence from the pathogenic
mutations within the genes for APP and presenilins 1 and
2 that are responsible for familial autosomal dominant AD.
Similar to DS, these mutations aﬀect APP processing causing
overproduction of Aβ42 [23, 24]. However, the possibility
that these familial forms of AD cannot be extended to
sporadic forms of the disease must be kept in mind.
One of the factors involved in AD susceptibility is
apolipoprotein E genotype with ε4 (APOE4) being a suscep-
tibility gene and major risk factor for sporadic and familial
AD [25, 26]. Also, in DS, the APOE4 allele increases the
risk for dementia and, in nondemented adults with DS,
those with at least one ε4 allele were approximately ﬁve
times more likely to die within a given followup period than
those without [27]. However, since both cases had the same
ApoE genotype (ε3/3), this cannot account for the marked
diﬀerence in AD-like pathology.
Even if only about half of the sites with NFT also show
Congo-red-positive Aβ plaques in the present study, the
strong correlation between ﬁbrillar, Congo-red-positive Aβ,
and NFT (15/15 sites) could support the view that NFT
formation occurs when Aβ is present in ﬁbrillar form [4,
28]. On the other hand, it has been proposed that the Aβ
peptides, and especially Aβ42, aggregate in a concentration-
dependentmannertoformcytotoxicprotoﬁbrilsthatfurther
accumulate to form amyloid plaques [5]. The ﬁnding of
similar loads of Aβ42 in two DS cases with divergent AD
pathologysuggeststhatotherfactor(s)mayplaycriticalroles.
Ingelsson et al. [29] have shown in sporadic AD that
amyloid plaques display a more widespread distribution
than NFT and reach a “ceiling” early in the disease process
before clinical symptoms become manifest, whereas NFT
formation, synaptic and neuronal loss, and gliosis continue
throughout the course of AD. Such an early ceiling eﬀect
might explain why our DS cases show similar Aβ accu-
mulation in spite of being at early and late stages of AD,
respectively. Nonetheless, a trigger mechanism other than
Aβ4 2a c c u m u l a t i o nw o u l dh a v et ob ei n v o k e dt oh a v ec a u s e d
progression of AD pathology.
This observation of two comparable DS cases with
respect to age at death, APOE genotype, and Aβ42 load does
not clarify why the AD-like pathology is so divergent in the
two cases, leaving this important question to be resolved
by future studies. A possible factor that could underlie the
diﬀerence in neuroﬁbrillary pathology, in spite of similar
overall Aβ42 load, relates to the potential neurotoxicity
mediated by preﬁbrillar or oligomeric forms of Aβ.R e c e n t
studies indicate that intraneuronal accumulation of Aβ42 as
soluble oligomers may serve as a trigger for progression of
AD pathology [30]. Also, only soluble oligomeric but not
ﬁbrillar Aβ(1-42) forms induced toxicity in cultured cholin-
ergic cells [31]. To this end, the assessment of intraneuronal
Aβ has been rendered easier through development of speciﬁc
antibodies suitable for immunohistochemistical studies of
human postmortem tissue [32]. Such studies may be able to
address the still unresolved role of Aβ in Alzheimer’s disease.
6. Conclusions
This descriptive study of two DS brains with similar age
at death and APOE genotype also revealed comparable
Aβ42 deposits while one was at an early stage and the
other at a late stage of AD-like pathology, suggesting that
the mere deposition of widespread Aβ42 is an insuﬃcient
explanation for AD progression. Even if Aβ42 deposition
may be a necessary link between genetically enhanced APP
metabolism and AD development, this limited observation
adds to other evidence questioning Aβ42’s central role in the
amyloid cascade hypothesis of AD pathogenesis.
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